drugset / Trial / NCT02872259
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the safety and efficacy of BGB324 given together with standard treatment, pembrolizumab or dabrafenib and trametinib, compared to standard treatment alone,
Timeline
- Start
- 2017-02-13
- Primary completion
- 2024-05-23
- Completion
- 2024-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bemcentinib | Small molecule | 100 mg | Oral |
| Subject | Bemcentinib | Small molecule | 200 mg | Oral |
| Comparator | Dabrafenib | Small molecule | 150 mg | Oral |
| Comparator | Pembrolizumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Comparator | Trametinib | Small molecule | 2 mg | Oral |